The foundation:

Alzheimer's & Dementia Journal publishes an article on MOPEAD

The renowned magazine Alzheimer & Dementia: The Journal of the Alzheimer's Association has focused on the European project MOPEAD (Models of Patient Engagement for Alzheimer's Disease), through the publication of an article that analyzes in depth the mechanisms of this initiative to promote the active participation of citizens in the early detection of dementia.

The project, led in Spain by Fundació ACE and promoted by the European Federation of Associations of the Pharmaceutical Industry (EFPIA) and the European Union through the IMI consortium (Innovative Medicines Initiative), has as main goal to consolidate a system that allows the diagnosis of dementia in mild phases, as well as awareness and the definition of innovative therapeutic interventions to stop Alzheimer's disease.

Facilitating early diagnosis of Alzheimer's

Entities from different European countries (Germany, Slovenia, Spain, Sweden and the Netherlands) carried out different participation models to compare their effectiveness when making an early diagnosis of Alzheimer's.

The mechanisms analyzed in the project are the following: the completion of an online questionnaire, Open Door Days in specialized memory centers, as well as tests of primary and tertiary care in health centers. In the current phase of the project, researchers are developing a comparison of the different models to determine their effectiveness.

Results by the end of 2019

The results of MOPEAD, which will be made public before the end of the year, will allow identifying and establishing, at European level, the most appropriate model to facilitate the access of citizens with mild cognitive impairment or memory complaints to an early diagnosis.

Read the full article here.



You might also like

New FACEHBI results support the effectiveness of a tool to measure blood amyloid levels

A study conducted with participants from the FACEHBI cohort supports the potential of a new tool that measures plasma β-amyloid levels to identify people in early stages of Alzheimer's disease.